Qualigen Therapeutics, Inc. (QLGN)
- Previous Close
3.5800 - Open
3.7295 - Bid --
- Ask --
- Day's Range
3.5200 - 3.7295 - 52 Week Range
2.8500 - 29.4500 - Volume
4,504 - Avg. Volume
61,696 - Market Cap (intraday)
2.592M - Beta (5Y Monthly) -0.03
- PE Ratio (TTM)
0.00 - EPS (TTM)
3,635.0000 - Earnings Date May 1, 2025 - May 7, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Qualigen Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development and commercialization of treatments for adult and pediatric cancer in the United States. The company's lead program is QN-302, an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor, which is in Phase 1a clinical trial for the treatment of pancreatic cancer and other solid tumors. It is also developing Pan-RAS that is in preclinical stage for the treatment of advanced solid tumors. Qualigen Therapeutics, Inc. was founded in 1996 and is based in Carlsbad, California.
www.qlgntx.comRecent News: QLGN
View More
Performance Overview: QLGN
Trailing total returns as of 5/1/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: QLGN
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: QLGN
View MoreValuation Measures
Market Cap
2.53M
Enterprise Value
3.58M
Trailing P/E
0.00
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-126.39%
Return on Equity (ttm)
--
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-7.86M
Diluted EPS (ttm)
3,635.0000
Balance Sheet and Cash Flow
Total Cash (mrq)
388.15k
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-6.57M